ArticleAmerican journal of nuclear medicine and molecular imaging2012
Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.
Article in American journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- CXCR4-directed theranostics in oncology and inflammation.Annals of nuclear medicine · 2018Review
- A Review on Green Synthesis, Biomedical Applications, and Toxicity Studies of ZnO NPs.Bioinorganic chemistry and applications · 2018Review
- Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.BMC cancer · 2017Article
- Molecular imaging agents for SPECT (and SPECT/CT).European journal of nuclear medicine and molecular imaging · 2014Review
- The intricate role of CXCR4 in cancer.Advances in cancer research · 2014Review
- Antibody-based imaging of HER-2: moving into the clinic.Current molecular medicine · 2013Review
- Functionalized upconversion nanoparticles: versatile nanoplatforms for translational research.Current molecular medicine · 2013Review
- Biomedical applications of zinc oxide nanomaterials.Current molecular medicine · 2013Review
- Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Current molecular medicine · 2013Review
- Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis.British journal of cancer · 2013Article
- Multimodality imaging of RNA interference.Current medicinal chemistry · 2013Review
- Article
- Immuno-PET of tissue factor in pancreatic cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2012Article
- In a "nutshell": intrinsically radio-labeled quantum dots.American journal of nuclear medicine and molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
The chemokine receptor 4 (CXCR4) is a biomarker that is over-expressed in ductal carcinoma in situ (DCIS). Hence, CXCR4-targeted (molecular) imaging approaches may have diagnostic value in such a challenging, premalignant lesion. The indium labeled CXCR4 peptide-antagonist, (111)In-DTPA-Ac-TZ14011, was used to visualize CXCR4-expression in a mammary intraepithelial neoplastic outgrowth (MIN-O) mouse tumor model resembling human DCIS. MIN-O lesion development was longitudinally monitored using SPET/CT and tracer uptake was compared to uptake in control lesions. Expression of CXCR4 was validated using immunohistochemistry and flow cytometric analysis. The uptake of (111)In-DTPA-Ac-TZ14011 was related to tumor angiogenesis using (111)In-cDTPA-[RGDfK]. Twenty-four hours after tracer injection, MIN-O lesions could be discriminated from low CXCR4-expressing control tumors, while the degree of angiogenesis based on the α(v)β(3) integrin expression in both tumor types was similar. The uptake of (111)In-DTPA-Ac-TZ14011 in early MIN-O lesions was significantly lower than in larger intermediate and late-stage lesions, two-and-a-half-times (p=0.03) and seven-times (p=0.002), respectively. Intermediate and late stage lesions show a higher degree of membranous CXCR4-staining at immunohistochemistry and flow cytometric analysis. From this study we can conclude that (111)In-DTPA-Ac-TZ14011 can be used to visualize the CXCR4-expression in MIN-O lesions longitudinally.
Indexed as
Identifiers
23133805PMC3478110W30730358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.